Senesco Technologies Inc (SNTI)

0.82
0.03 3.53
OTC : Health Care
Prev Close 0.85
Open 0.81
Day Low/High 0.78 / 0.85
52 Wk Low/High /
Volume 35.90K
Avg Volume 20.60K
Exchange OTC
Shares Outstanding 13.85M
Market Cap 22.02M
EPS -2.53
P/E Ratio N/A
Div & Yield N.A. (N.A)

Sevion Therapeutics Reports Fiscal Year 2014 Financial Results

Senesco Technologies, Inc. doing business as Sevion Therapeutics ("Sevion" or the "Company") (OTCQB:SNTI) today reported financial results for the fiscal year ended June 30, 2014 (“Fiscal 2014”), and also...

Senesco Announces Corporate Rebranding To Sevion Therapeutics

Senesco Technologies, Inc. (OTCQB:SNTI) (the “Company” or “Sevion”), a clinical-stage company which discovers, develops and acquires next-generation biologics for the treatment of cancer and...

Senesco Closes Enrollment In Its Phase 1b/2a SNS01-T Study

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI) today announced the closing of enrollment in its ongoing Phase 1b/2a open-label, multiple-dose, dose-escalation clinical trial of...

Senesco Announces New CEO

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB: SNTI) announced the appointment of Ronald A.

Senesco To Update On R&D Plans At BIO

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB:SNTI), announced that Vaughn S.

Senesco Announces Update On SNS01-T At ASCO

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB:SNTI), announced that Alice Bexon, M.

Senesco Completes Acquisition Of Fabrus, An OPKO Portfolio Company

OPKO Health, Inc. (NYSE:OPK), a multi-national biopharmaceutical and diagnostics company, today reported that Senesco Technologies, Inc.

Senesco Completes Acquisition Of Fabrus

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI), completed its acquisition of Fabrus, Inc.

Senesco Technologies Reports Second Quarter Of Fiscal Year 2014 Financial Results

Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB:SNTI) today announced financial results for the three months ended March 31, 2014 (“Third Quarter 2014”).

Senesco Announces Presentation On The Effectiveness Of EIF5A In Inhibiting Tumor Progression In Liver Cancer Models

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB:SNTI), announced today that an oral presentation will be delivered on its potential approach to treating hepatocellular carcinoma at the...

Senesco Opens Two New Clinical Trial Sites And Initiates Treatment Of The First Patient In South Africa

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI) reported the opening of two new sites in the Republic of South Africa at Pretoria East Hospital and Groote Schuur Hospital in Cape...

Senesco Pays Off Line Of Credit

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB: SNTI) announces that is has paid in full and canceled the line of credit held by JMP Securities (the “Line of Credit”).

In Non-clinical Cancer Studies Senesco’s Therapeutic Candidate, SNS01-T, Works Synergistically In Combination With The Active Components Of Revlimid® And Velcade®

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI) announced the publication in the peer-reviewed journal Molecular Therapy, the official journal of the American Society for Gene...

Senesco Technologies Reports Second Quarter Of Fiscal Year 2014 Financial Results

Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB:SNTI) today announced financial results for the three months ended December 31, 2013 (“Second Quarter 2014”).

First Patient In Cohort 4 Receives Infusion Of Senesco’s Therapeutic Candidate, SNS01-T, For The Treatment Of Multiple Myeloma And Non-Hodgkins Lymphoma In Phase 1b/2a Clinical Trial

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI) reported the administration of SNS01-T to the first patient in cohort 4 of its Phase 1b/2a study in multiple myeloma and...

Senesco To Present At Biotech Showcase™ 2014

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI), today announced that Leslie J.

Senesco Announces Letter of Intent to Merge with Fabrus

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI), today announced that it has agreed to terms and executed a non-binding Letter of Intent to merge with Fabrus, Inc...

Senesco Announces Up To $25.2 Million Equity Financing

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI) announced today that it has entered into a securities purchase agreement with certain investors to raise up to $25.

Senesco’s Drug Candidate SNS01-T Selectively Kills Cancer Cells And Not Healthy Cells In Disease Models

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB: SNTI) reported results of preclinical studies with SNS01-T at the 55th American Society of Hematology Annual Meeting in New Orleans.

Senesco Announces Results Of Cohort 3 In SNS01-T Phase 1b/2a Trial

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI) reported results of cohort 3 in its Phase 1b/2a clinical study of SNS01-T at the 55th American Society of Hematology Annual Meeting...

Completion Of Cohort 3 In Phase 1b/2a Study In Multiple Myeloma And Non-Hodgkins B-Cell Lymphoma

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI) reported today the completion of cohort 3 of its Phase 1b/2a clinical trial for its drug, SNS01-T, for the treatment of multiple...

Senesco To Provide Update On Its Phase 1b/2a Trial Progress At 55th American Society Of Hematology Annual Meeting

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI) announced today that it will make two presentations on its gene regulation technology (SNS01-T) for blood-borne cancer care at the...

Senesco Announces Reverse Stock Split

Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB:SNTI) today announced a 1-for-100 reverse split of its issued and outstanding shares of common stock.

Senesco Announces $1.725 Million Equity Financing

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI) announced today that it has entered into a securities purchase agreement with certain investors to raise $1.

Senesco Technologies Reports Fiscal Year 2013 Financial Results

Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB:SNTI) today announced financial results for the 12 months ended June 30, 2013 (“Fiscal 2013”).

Senesco Announces Results Of Cohort 2 Of Its SNS01-T Phase 1b/2a Trial

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI) reported results of cohort 2 in its Phase 1b/2a clinical study of SNS01-T.

Senesco Technologies Provides Corporate Update

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB: SNTI) provides the following update on Company activities.

Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB: SNTI) today reported financial results for the second quarter of fiscal year 2013 which ended on December 31, 2012.

Senesco Technologies, Inc. Investor Presentation Now Available For On-demand Viewing At RetailInvestorConferences.com

Company invites individual and institutional investors to log-on to view presentation

Senesco To Webcast, Live, At RetailInvestorConferences.com On February 7th

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB: SNTI) today announced that Leslie J.